Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus MR Conversion in Stable Liver Transplant
NCT00282243Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2003
- Primary completion
- Oct 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus + Wuzhi capsule in Liver transplant rejection, sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to 24 Hours, Minimum Observed Concentration of Tacrolimus at Day 56 and 2 more. Started Feb 2003; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00282243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282243.